AP3371A - Anti-IGF antibodies - Google Patents

Anti-IGF antibodies

Info

Publication number
AP3371A
AP3371A AP2011005719A AP2011005719A AP3371A AP 3371 A AP3371 A AP 3371A AP 2011005719 A AP2011005719 A AP 2011005719A AP 2011005719 A AP2011005719 A AP 2011005719A AP 3371 A AP3371 A AP 3371A
Authority
AP
ARIPO
Prior art keywords
igf antibodies
igf
antibodies
Prior art date
Application number
AP2011005719A
Other languages
English (en)
Other versions
AP2011005719A0 (en
Inventor
Paul Adam
Eric Borges
Original Assignee
Boehringer Ingelheim Inernat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Inernat Gmbh filed Critical Boehringer Ingelheim Inernat Gmbh
Publication of AP2011005719A0 publication Critical patent/AP2011005719A0/xx
Application granted granted Critical
Publication of AP3371A publication Critical patent/AP3371A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AP2011005719A 2008-12-12 2009-12-11 Anti-IGF antibodies AP3371A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08171554 2008-12-12
PCT/EP2009/066894 WO2010066868A2 (en) 2008-12-12 2009-12-11 Anti-igf antibodies

Publications (2)

Publication Number Publication Date
AP2011005719A0 AP2011005719A0 (en) 2011-06-30
AP3371A true AP3371A (en) 2015-07-31

Family

ID=40512371

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005719A AP3371A (en) 2008-12-12 2009-12-11 Anti-IGF antibodies

Country Status (39)

Country Link
US (4) US8318159B2 (hu)
EP (2) EP3064219A3 (hu)
JP (2) JP5694184B2 (hu)
KR (1) KR101827332B1 (hu)
CN (3) CN103396487A (hu)
AP (1) AP3371A (hu)
AR (1) AR074726A1 (hu)
AU (1) AU2009324296B2 (hu)
BR (1) BRPI0923359B8 (hu)
CA (1) CA2740341C (hu)
CL (1) CL2011001431A1 (hu)
CO (1) CO6390042A2 (hu)
CY (1) CY1117241T1 (hu)
DK (1) DK2376116T3 (hu)
EA (1) EA029178B1 (hu)
EC (1) ECSP11011126A (hu)
ES (1) ES2561045T3 (hu)
GE (1) GEP20146119B (hu)
HK (1) HK1158933A1 (hu)
HR (1) HRP20160190T1 (hu)
HU (1) HUE026374T2 (hu)
IL (1) IL212047A (hu)
MA (1) MA32888B1 (hu)
ME (1) ME02377B (hu)
MX (1) MX2011006055A (hu)
MY (1) MY150984A (hu)
NZ (3) NZ597694A (hu)
PE (1) PE20120415A1 (hu)
PL (1) PL2376116T3 (hu)
PT (1) PT2376116E (hu)
RS (1) RS54423B1 (hu)
SG (2) SG2014013841A (hu)
SI (1) SI2376116T1 (hu)
TN (1) TN2011000299A1 (hu)
TW (1) TWI471139B (hu)
UA (1) UA105198C2 (hu)
UY (1) UY32317A (hu)
WO (1) WO2010066868A2 (hu)
ZA (1) ZA201102308B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101477824B1 (ko) 2006-09-29 2015-01-02 온코메드 파마슈티칼스, 인크. 암의 진단 및 치료를 위한 조성물 및 방법
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
JP5607530B2 (ja) 2007-09-04 2014-10-15 コンピュゲン エルティーディー． ポリペプチド並びにポリヌクレオチド、並びに薬剤および生物製剤生産のための薬剤標的としてのその利用
EP2356148A2 (en) 2008-11-10 2011-08-17 Novartis AG Antibodies to modified human igf-1/e peptides
AU2009324296B2 (en) 2008-12-12 2016-07-28 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
TR201818814T4 (tr) 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
WO2011053779A2 (en) * 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012068148A1 (en) * 2010-11-16 2012-05-24 Medimmune, Llc Regimens for treatments using anti-igf antibodies
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
RS58201B1 (sr) 2011-09-23 2019-03-29 Oncomed Pharm Inc Vegf/dll4 vezujući agensi i njihova upotreba
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
TWI750197B (zh) * 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
CN102863530A (zh) * 2012-09-26 2013-01-09 李彬 一种脂肪细胞分化代谢产物igf-1抗体及包含该抗体的芯片以及应用
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
BR112015027385A2 (pt) 2013-04-29 2017-08-29 Hoffmann La Roche Anticorpos modificados de ligação ao fcrn humano e métodos de uso
KR102356757B1 (ko) * 2013-10-18 2022-02-03 노바셉 이큅먼트 솔루션즈 단백질 정제
JP2017502025A (ja) * 2013-12-19 2017-01-19 メディミューン，エルエルシー 肉腫を治療するための組成物および方法
WO2015107015A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
WO2015110560A1 (en) * 2014-01-24 2015-07-30 Boehringer Ingelheim International Gmbh Cancer treatment using an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016113572A1 (en) * 2015-01-16 2016-07-21 The University Of Liverpool Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy
EP3341021A4 (en) * 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
WO2017055291A1 (en) 2015-09-28 2017-04-06 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN105622730B (zh) * 2016-02-18 2020-06-26 深圳华尔康生物科技有限公司 一种特异性结合igf-1的多肽及其应用
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
JP6908709B2 (ja) 2017-01-06 2021-07-28 エービーエル バイオ インコーポレイテッド 抗α−ｓｙｎ抗体およびその使用
JP2020535180A (ja) * 2017-09-29 2020-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療
EP3725806A4 (en) 2017-12-14 2022-03-30 ABL Bio Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
CN111372932B (zh) 2017-12-21 2023-11-21 勃林格殷格翰国际有限公司 作为sos1抑制剂的新颖苄氨基取代吡啶并嘧啶酮及衍生物
KR102404684B1 (ko) * 2019-01-15 2022-06-07 서울대학교산학협력단 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
PE20240493A1 (es) 2020-06-02 2024-03-15 Boehringer Ingelheim Int 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer
AU2021409816A1 (en) 2020-12-22 2023-07-06 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
CN115232111A (zh) 2021-04-23 2022-10-25 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN118591540A (zh) 2021-12-01 2024-09-03 勃林格殷格翰国际有限公司 包含环状2-氨基-3-氰基噻吩的kras降解化合物
CA3240980A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN118574835A (zh) 2021-12-01 2024-08-30 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
CN114671949B (zh) * 2022-04-20 2023-04-28 山西农业大学 一种igf1纳米抗体及其应用
WO2023225657A2 (en) * 2022-05-20 2023-11-23 Rezolute, Inc. Formulations for anti-insulin receptor antibody and uses thereof
KR20240053520A (ko) * 2022-10-14 2024-04-24 포항공과대학교 산학협력단 Igf-1 수용체 결합 압타머 및 이의 용도
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505075A1 (en) * 2002-04-30 2005-02-09 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
ATE95236T1 (de) 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
AU1232188A (en) 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
DE68908175T2 (de) 1988-05-27 1994-03-03 Centocor Inc Gefriergetrocknete formulierung für antikörperprodukte.
AU630882B2 (en) 1988-06-30 1992-11-12 City Of Hope Insulinomimetic and insulin receptor binding site peptides
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
AU678483B2 (en) 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
WO1995025794A1 (fr) 1994-03-23 1995-09-28 Japan Clinical Laboratories Anticorps monoclonal anti-igf-i
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DE69834828T2 (de) 1997-11-27 2007-01-04 Commonwealth Scientific And Industrial Research Organisation Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
KR100816572B1 (ko) 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
DZ3494A1 (fr) 2001-01-05 2002-07-11 Pfizer Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1806364B1 (fr) 2002-01-18 2013-07-31 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et leurs applications
JP2003310275A (ja) 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd ヒトインスリン様成長因子に対する遺伝子組換え抗体
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
SI1517921T1 (sl) 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
US20030138430A1 (en) * 2002-09-20 2003-07-24 Stimmel Julie Beth Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2514231A1 (en) 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
WO2004083248A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
EP1661582A1 (en) 2003-08-21 2006-05-31 Kyowa Hakko Kogyo Co., Ltd. Cancer metastasis inhibitor
ATE492562T1 (de) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin- like growth factor
WO2005027970A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. 癌治療用医薬
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
EP2322217A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1888647A2 (en) 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
SI2860192T1 (en) 2005-10-12 2018-04-30 Morphosys Ag Generating and profiling fully human HuCAL GOLD-specific therapeutic antibodies specific to human CD38
DK1979001T3 (da) 2005-12-13 2012-07-16 Medimmune Ltd Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
EA017265B1 (ru) 2006-02-03 2012-11-30 Имклоун Элэлси Применение антитела imc-a12, которое является ингибитором igf-ir, для лечения рака предстательной железы
EP1999149A4 (en) 2006-03-28 2010-01-20 Biogen Idec Inc ANTI-IGF-1R ANTIBODIES AND USES THEREOF
EP2010567A2 (en) * 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Antibody compositions and methods for treatment of neoplastic disease
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
PT2027470E (pt) 2006-06-02 2013-01-28 Pfizer Prod Inc Ensaio de células tumorais circulantes
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
US7749966B2 (en) 2006-12-21 2010-07-06 Boston Biomedical Research Institute Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
GB0702888D0 (en) 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
AU2008223541B2 (en) 2007-03-02 2012-04-05 Amgen Inc. Methods and compositions for treating tumor diseases
WO2008115470A2 (en) 2007-03-16 2008-09-25 East Carolina University Hox-gene expression as a biomarker for igf-1r therapeutics
CN101668540A (zh) 2007-03-22 2010-03-10 英克隆有限责任公司 稳定的抗体制剂
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2008152422A2 (en) 2007-06-12 2008-12-18 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof-909
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009006336A1 (en) 2007-06-28 2009-01-08 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
AU2008282863A1 (en) 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
CA2694055A1 (en) 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
EP2183275B1 (en) 2007-08-03 2014-10-29 Affibody AB Igf-1r binding polypeptides and their use
US8420315B2 (en) 2007-08-06 2013-04-16 Orion Genomics Llc Single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
CA2697612A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
US20090130105A1 (en) 2007-08-28 2009-05-21 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
AU2008302076B2 (en) 2007-09-19 2015-06-11 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
AU2008307579A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2694154A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
JP2011505873A (ja) 2007-12-18 2011-03-03 シェーリング コーポレイション 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
US20090258365A1 (en) 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
EP2274010A1 (en) 2008-04-11 2011-01-19 Biogen Idec MA Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
EP2282739A2 (en) 2008-05-05 2011-02-16 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
AU2009244091B2 (en) 2008-05-09 2014-11-27 Commonwealth Scientific And Industrial Research Organisation IGF-II/GF-IIE binding proteins
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102224239A (zh) 2008-09-26 2011-10-19 先灵公司 高效价抗体生产
AU2009296297A1 (en) 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-EGFR/anti-IGF-1R antibodies
US20110262446A1 (en) 2008-10-14 2011-10-27 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
US8163509B2 (en) 2008-10-20 2012-04-24 The Regents Of The University Of Colorado, A Body Corporate Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2356148A2 (en) 2008-11-10 2011-08-17 Novartis AG Antibodies to modified human igf-1/e peptides
US20100172862A1 (en) 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
AU2009324296B2 (en) 2008-12-12 2016-07-28 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
JP2012513477A (ja) 2008-12-23 2012-06-14 ソーク インスティチュート フォー バイオロジカル スタディーズ 神経変性疾患の治療方法
CA2757730A1 (en) 2009-04-16 2010-10-21 Merck Sharp & Dohme Corp. Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
WO2011057064A1 (en) 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
EP2852685A1 (en) 2012-03-30 2015-04-01 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
WO2013169611A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Compositions and methods for treating breast cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2015110560A1 (en) 2014-01-24 2015-07-30 Boehringer Ingelheim International Gmbh Cancer treatment using an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus
WO2017055291A1 (en) 2015-09-28 2017-04-06 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505075A1 (en) * 2002-04-30 2005-02-09 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOYA MASATO ET AL: "Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 64, no. 17, 1 January 2004 (2004-01-01), pages 6252-6258, XP002982679 *
MAÑES S ET AL: "Functional epitope mapping of insulin-like growth factor I (IGF-I) by anti-IGF-I monoclonal antibodies" ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 138, no. 3, 1 March 1997 (1997-03-01), pages 905-915, XP002436109 *
MANES S ET AL: "PHYSICAL MAPPING OF HUMAN INSULIN-LIKE GROWTH FACTOR-I USING SPECIFIC MONOCLONAL ANTIBODIES" JOURNAL OF ENDOCRINOLOGY, BRISTOL, GB, vol. 154, no. 2, 1 January 1997 (1997-01-01), pages 293-302, XP008063540 *
MIYAMOTO SHIN'ICHI ET AL: "Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers" CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 9, 1 May 2005 (2005-05-01), pages 3494-3502, XP002414392 *

Also Published As

Publication number Publication date
US11299538B2 (en) 2022-04-12
WO2010066868A2 (en) 2010-06-17
DK2376116T3 (en) 2016-02-29
EP2376116A2 (en) 2011-10-19
CO6390042A2 (es) 2012-02-29
RS54423B1 (en) 2016-04-28
CY1117241T1 (el) 2017-04-05
IL212047A0 (en) 2011-06-30
PT2376116E (pt) 2016-02-24
SG2014013841A (en) 2014-07-30
CA2740341A1 (en) 2010-06-17
JP2012511315A (ja) 2012-05-24
MX2011006055A (es) 2011-07-04
TW201026327A (en) 2010-07-16
TN2011000299A1 (en) 2012-12-17
WO2010066868A3 (en) 2010-09-10
US8318159B2 (en) 2012-11-27
AU2009324296B2 (en) 2016-07-28
BRPI0923359B8 (pt) 2021-05-25
HRP20160190T1 (hr) 2016-03-25
ZA201102308B (en) 2011-12-28
NZ597694A (en) 2013-08-30
NZ592151A (en) 2012-10-26
US20150010574A1 (en) 2015-01-08
CN103396488A (zh) 2013-11-20
NZ597692A (en) 2013-08-30
UA105198C2 (ru) 2014-04-25
BRPI0923359B1 (pt) 2020-09-15
ES2561045T3 (es) 2016-02-24
CN103396487A (zh) 2013-11-20
EA201100918A1 (ru) 2012-01-30
EP3064219A2 (en) 2016-09-07
EP2376116B1 (en) 2015-12-09
TWI471139B (zh) 2015-02-01
PE20120415A1 (es) 2012-05-09
SI2376116T1 (sl) 2016-03-31
HUE026374T2 (hu) 2016-05-30
ME02377B (me) 2016-06-20
IL212047A (en) 2016-03-31
MA32888B1 (fr) 2011-12-01
BRPI0923359A2 (pt) 2015-07-21
CN102227226B (zh) 2015-05-13
GEP20146119B (en) 2014-07-25
EP3064219A3 (en) 2016-09-28
HK1158933A1 (en) 2012-07-27
UY32317A (es) 2010-07-30
JP5694184B2 (ja) 2015-04-01
SG172107A1 (en) 2011-07-28
ECSP11011126A (es) 2011-07-29
AR074726A1 (es) 2011-02-09
CA2740341C (en) 2019-05-07
EA029178B1 (ru) 2018-02-28
CN102227226A (zh) 2011-10-26
KR101827332B1 (ko) 2018-02-09
PL2376116T3 (pl) 2016-07-29
KR20110094034A (ko) 2011-08-19
US20190225681A1 (en) 2019-07-25
MY150984A (en) 2014-03-31
AP2011005719A0 (en) 2011-06-30
US10179810B2 (en) 2019-01-15
AU2009324296A1 (en) 2010-06-17
CL2011001431A1 (es) 2012-02-17
JP2015131812A (ja) 2015-07-23
US20130230541A1 (en) 2013-09-05
US20100150940A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
AP3371A (en) Anti-IGF antibodies
ZA201005348B (en) Humanized anti-c5ar antibodies
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
IL214996A0 (en) Anti-bcma antibodies
EP2331579A4 (en) MONOCLONAL ANTIBODIES
GB0920127D0 (en) Antibodies
ZA201102119B (en) Improved antibody libraies
GB0909906D0 (en) Antibodies
GB0821100D0 (en) Antibodies
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
EP2259795A4 (en) ANTI-VEGF ANTIBODY
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
EP2483416A4 (en) MONOCLONAL ANTIBODIES
IL236236A (en) Antibodies to the fam26f polypeptide
ZA201006099B (en) Anti-tyrp1 antibodies
GB0920324D0 (en) Antibodies
HK1170745A1 (en) Antibodies against il-17br il-17br
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2424892A4 (en) DC-STAMP ANTIBODY
GB0911770D0 (en) Antibody
GB0823562D0 (en) Antibodies
GB0806230D0 (en) Antibodies
GB0817621D0 (en) Antibody